|Application ||WB, E|
|Other Accession||P14408, P10173, Q60HF9, NP_000134.2|
|Predicted||Monkey, Pig, Rat|
|Calculated MW||54637 Da|
|Antigen Region||35-63 aa|
|Other Names||Fumarate hydratase, mitochondrial, Fumarase, FH|
|Target/Specificity||This FH antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 35-63 amino acids from the N-terminal region of human FH.|
|Format||Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||FH Antibody (N-term) (Ascites) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Also acts as a tumor suppressor.|
|Cellular Location||Isoform Mitochondrial: Mitochondrion.|
|Tissue Location||Expressed in red blood cells; underexpressed in red blood cells (cytoplasm) of patients with hereditary non- spherocytic hemolytic anemia of unknown etiology|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene is an enzymatic component of the tricarboxylic acid (TCA) cycle, or Krebs cycle, and catalyzes the formation of L-malate from fumarate. It exists in both a cytosolic form and an N-terminal extended form, differing only in the translation start site used. The N-terminal extended form is targeted to the mitochondrion, where the removal of the extension generates the same form as in the cytoplasm. It is similar to some thermostable class II fumarases and functions as a homotetramer. Mutations in this gene can cause fumarase deficiency and lead to progressive encephalopathy.
Shimada, M., et al. Hum. Genet. 128(4):433-441(2010)
Allegri, G., et al. J. Inherit. Metab. Dis. 33(4):411-419(2010)
Yogev, O., et al. PLoS Biol. 8 (3), E1000328 (2010) :
Yang, Y., et al. Cancer Genet. Cytogenet. 196(1):45-55(2010)
Rikova, K., et al. Cell 131(6):1190-1203(2007)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.